Key facts
- Eyestem’s last known valuation is $46.9M (Jul 2022).
- It has raised $20.0M; the latest was Later Stage VC ($10.0M) in Aug 2025.
- Notable investors include BIRAC, Alkem Laboratories, Anurag Bagaria, Biological E, Centre for Cellular And Molecular Platforms — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Eyestem
- ·The full record, as it builds
Funding rounds
No funding rounds for Eyestem are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eyestem
Developer of scalable cell replacement therapies designed to treat incurable diseases. The company's platform aims to replace damaged photoreceptor cells in the eye with healthy, transplantable cells derived from induced pluripotent stem cells to restore vision in patients with conditions like dry age-related macular degeneration, enabling healthcare professionals to offer treatments to patients.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2015
- Employees
- 10
- Website
- eyestem.com/
- Ownership
- Privately Held (backing)
Eyestem doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eyestem shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eyestem in its N-PORT filings yet. We sweep new filings monthly.